APA (7th ed.) Citation

Valerio, M. R., Sambataro, D., Martorana, F., Greco, M., Mesi, C., Gebbia, V., . . . Scandurra, G. (2026). Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. Current Oncology, 33(4), 198. https://doi.org/10.3390/curroncol33040198

Chicago Style (17th ed.) Citation

Valerio, Maria Rosaria, Daniela Sambataro, Federica Martorana, Martina Greco, Chiara Mesi, Vittorio Gebbia, Paolo Vigneri, and Giuseppa Scandurra. "Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review." Current Oncology 33, no. 4 (2026): 198. https://doi.org/10.3390/curroncol33040198.

MLA (9th ed.) Citation

Valerio, Maria Rosaria, et al. "Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review." Current Oncology, vol. 33, no. 4, 2026, p. 198, https://doi.org/10.3390/curroncol33040198.